Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma


Phase II Study Of PS-341 For Patients With High-Risk, Newly Diagnosed Multiple Myeloma


Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.


This phase II trial is studying how well bortezomib works in treating patients with newly diagnosed high-risk stage III multiple myeloma.

Study Status: Completed


Condition Intervention Phase
Multiple Myeloma
Plasma Cell Neoplasm
Drug: PS-341 Phase 2

Verified by National Cancer Institute (NCI) October, 2012

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI) identifier: NCT00075881

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Angela Dispenzieri, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site